By Authority Clause Examples

By Authority. The Authority shall not terminate or refuse to renew the Lease other than for good cause. Good cause is defined as: 1. Serious or repeated violations of material terms of the Lease now or as it may be subsequently amended, including terms found in any addendums, rules of occupancy, and any other policies or rules of Authority which are incorporated herein; or 2. Failure to make timely payments due under the Lease, including the failure to pay rent or other charges when due, the failure to pay utility bills (for those utilities which Tenant is responsible to pay), and repeated late payment, which is three or more late payments within a 12‐month period; Failure to repay debt, failure to enter into a repayment agreement or breach a repayment agreement Authority will pursue other modes of collection); or 3. Misrepresentation or failure to disclose information regarding family income, assets, or composition or any other material facts affecting the eligibility of Tenant or household. This includes, but is not limited to discovery after lease up of facts that made Tenant ineligible for subsidy at the Premises and/or for federal housing programs; or 4. Discovery of material false statements or fraud by the Tenant in connection with an application for residency/assistance or with reexamination of income/eligibility; or 5. Failure to supply, in a timely fashion, any certification, release, information, or documentation regarding family income or composition needed to process annual re‐ examination or interim redeterminations; or 6. Serious or repeated damage and/or creation of physical hazards or safety risks in, at, to, or on the Premises, grounds, common areas, building external lot, or parking areas of an Authority owned or managed property; or 7. Criminal activity by ▇▇▇▇▇▇, household members, ▇▇▇▇▇▇’s guests, or another person under ▇▇▇▇▇▇’s control as follows: i. Any criminal activity that threatens the health or safety of other residents (including their household members and guests/visitors), agents or employees of Authority, or of neighbors residing near the Premises; ii. Any criminal activity that threatens the right to peaceful enjoyment of the Premises by other residents (including their household members and guests/visitors), by agents or employees of Authority residing at the building where Premises is located, or of neighbors residing near the Premises; iii. Any drug‐related criminal activity engaged in, on or off the premises, which means the illega...
View SourceView Similar (2)
By Authority. Authority may assign any of its rights or duties upon notice to Customer but any such assignment shall bind the assignee to this Agreement.
View Source
By Authority. The Authority may, by not less than 15 (fifteen) days’ written notice of termination to the Consultant, such notice to be given after the occurrence of any of the events specified in this Clause 2.9.1, terminate this Agreement if: a) the Consultant fails to remedy any breach hereof or any failure in the performance of its obligations hereunder, as specified in a notice of suspension pursuant to Clause 2.8 hereinabove, within 15 (fifteen) days of receipt of such notice of suspension or within such further period as the Authority may have subsequently granted in writing; b) the Consultant becomes insolvent or bankrupt or enters into any agreement with its creditors for relief of debt or take advantage of any law for the benefit of debtors or goes into liquidation or receivership whether compulsory or voluntary; c) the Consultant fails to comply with any final decision reached as a result of arbitration proceedings pursuant to Clause 9 hereof; d) the Consultant submits to the Authority a statement which has a material effect on the rights, obligations or interests of the Authority and which the Consultant knows to be false; e) any document, information, data or statement submitted by the Consultant in its Proposals, based on which the Consultant was considered eligible or successful, is found to be false, incorrect or misleading f) as the result of Force Majeure, the Consultant is unable to perform a material portion of the Services for a period of not less than 60 (sixty) days; or g) the Authority, in its sole discretion and for any reason whatsoever, decides to terminate this Agreement
View Source
By Authority. The Authority will have no right to terminate this MOU for any reason whatsoever, unless one or more of the following default events has occurred and the Authority has complied with Section 6.1(E): 1. If a default by the County is made in the payment of all or any portion of the MOU Service Fee or any other amount due hereunder and such default continues for a period of twenty (20) Business Days after receipt of written notice thereof. 2. If a default is made by a Party in the performance or observance of any covenant, agreement or condition on its part provided in this MOU (other than a default described in clause (1) above), and such default continues for a period of thirty (30) days after written notice thereof is given to the defaulting Party, with simultaneous notice given to all non- defaulting Parties, provided that if such default is capable of being remedied but cannot be remedied within such thirty (30) day period it will not constitute a basis for termination hereunder if corrective action is instituted by the defaulting Party within such period and diligently pursued until the default is remedied. 3. If the County files a petition or otherwise seeks relief under any federal or state bankruptcy or similar law.
View Source
By Authority. Without thereby implying any restriction on the AUTHORITY otherwise assigning, transferring, dealing with or granting rights in or over all or any of its rights or obligations under this Agreement, it is expressly recognized that, without requiring the consent of the SPC: i. the AUTHORITY may assign the benefit of or create any other encumbrance upon all or any of its rights hereunder; and ii. the AUTHORITY may assign and transfer all or any of its rights and obligations under this Agreement subject to the AUTHORITY guaranteeing to procure full and complete observance and performance of all such obligations by the assignee (such guarantee to be in a form reasonably acceptable to the SPC).
View Source
By Authority. The Authority shall not terminate or refuse to renew the Lease other than for good cause. Good cause is defined as: (i) Serious or repeated violations of material terms of the Lease now or as it may be subsequently amended, including terms found in any addendums, rules of occupancy, and any other policies or rules of Authority which are incorporated herein; or (ii) Failure to make timely payments due under the Lease, including the failure to pay rent or other charges when due, the failure to pay utility bills (for those utilities which Tenant is responsible to pay), and repeated late payment, which is three or more late payments within a 12-month period; Failure to repay debt, failure to enter into a repayment agreement or breach a repayment agreement (Authority will pursue other modes of collection); or (iii) Misrepresentation or failure to disclose information regarding family income, assets, or composition or any other material facts affecting the eligibility of Tenant or household. This includes, but is not limited to discovery after lease up of facts that made Tenant ineligible for subsidy at the Premises and/or for federal housing programs; or (iv) Discovery of material false statements or fraud by the Tenant in connection with an application for residency/assistance or with reexamination of income/eligibility; or (v) Failure to supply, in a timely fashion, any certification, release, information, or documentation regarding family income or composition needed to process annual re- examination or interim redeterminations; or (vi) Serious or repeated damage and/or creation of physical hazards or safety risks in, at, to, or on the Premises, grounds, common areas, building external lot, or parking areas of an Authority owned or managed property; or (vii) Criminal activity by ▇▇▇▇▇▇, household members, ▇▇▇▇▇▇’s guests, or another person under ▇▇▇▇▇▇’s control as follows: a. Any criminal activity that threatens the health or safety of other residents (including their household members and guests/visitors), agents or employees of Authority, or of neighbors residing near the Premises; b. Any criminal activity that threatens the right to peaceful enjoyment of the Premises by other residents (including their household members and guests/visitors), by agents or employees of Authority residing at the building where Premises is located, or of neighbors residing near the Premises; c. Any drug-related criminal activity engaged in, on or off the premises, which mean...
View Source

Related to By Authority

  • Regulatory Authority If any regulatory authority having jurisdiction (or any successor boards or agencies), a court of competent jurisdiction or other Governmental Authority with the appropriate jurisdiction (collectively, the ''Regulatory Body'') issues a rule, regulation, law or order that has the effect of cancelling, changing or superseding any term or provision of this Agreement (the ''Regulatory Requirement''), then this Agreement will be deemed modified to the extent necessary to comply with the Regulatory Requirement. Notwithstanding the foregoing, if a Regulatory Body materially modifies the terms and conditions of this Agreement and such modification(s) materially affect the benefits flowing to one or both of the Parties, as determined by either of the Parties within twenty (20) business days of the receipt of the Agreement as materially modified, the Parties agree to attempt in good faith to negotiate an amendment or amendments to this Agreement or take other appropriate action(s) so as to put each Party in effectively the same position in which the Parties would have been had such modification not been made. In the event that, within sixty (60) days or some other time period mutually agreed upon by the Parties after such modification has been made, the Parties are unable to reach agreement as to what, if any, amendments are necessary and fail to take other appropriate action to put each Party in effectively the same position in which the Parties would have been had such modification not been made, then either Party shall have the right to unilaterally terminate this Agreement forthwith.

  • Statutory Authority Connecticut General Statute §§ 10a-104, 10a-108, 4a-52a, and 10a-151b provide the University with authority to enter into contracts in the pursuit of its mission.

  • Company Authority The Company has all requisite corporate power and authority to enter into and perform this Agreement and to consummate the transactions contemplated herein.

  • Necessary Authority The Scheduling Coordinator represents and warrants that all of the entities which it identifies on Schedule 1 as Scheduling Coordinator Metered Entities that it represents have granted it all necessary authority to enable it to carry out its obligations under this Agreement and the CAISO Tariff, and, subject to the execution and delivery by the CAISO, this Agreement will be enforceable against the Scheduling Coordinator in accordance with its terms.

  • Regulatory Authorities Except as described in the Registration Statement, the General Disclosure Package and the Prospectus, the Company and its subsidiaries: (i) are in compliance in all material respects with all statutes, rules, regulations, ordinances, orders and decrees applicable to the ownership, testing, in humans or laboratory models, development, manufacture, formulation, packaging, processing, recordkeeping, use, distribution, marketing, labeling, promotion, sale, price reporting, reimbursement, storage, import, export or disposal of any product manufactured or distributed by or for the Company or any of its subsidiaries (“Applicable Laws”), except where the failure to so comply would not, individually or in the aggregate, result in a Material Adverse Effect; (ii) to the knowledge of Company and its subsidiaries, have not, either voluntarily or involuntarily, disclosed to any governmental authority any violations of Applicable Laws, except such as would not, individually or in the aggregate, result in a Material Adverse Effect; (iii) have not received any Food and Drug Administration (“FDA”) Form 483 or any foreign counterpart thereof, warning letter, clinical hold notice or untitled letter from the FDA, any Institutional Review Board (as defined by federal regulation at 21 CFR Section 56.102(g)) or any other governmental authority alleging or asserting noncompliance with any Applicable Laws or any licenses, approvals, clearances, authorizations, permits and supplements or amendments thereto required by any such Applicable Laws (“Authorizations”), except such as would not, individually or in the aggregate, result in a Material Adverse Effect; (iv) have not received notification of nor have reason to believe that any audits by a governmental authority have resulted in a determination that any of their respective products have been improperly reimbursed, except such audits and determinations as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; (v) possess all Authorizations (including, without limitation, exemptions under any Investigational Device Exemption or Investigational New Drug Application, as described at 21 CFR Sections 312 and 812, and approvals of any Institutional Review Board), which are in full force and effect, required for the conduct of their respective businesses (and such Authorizations are valid and in full force and effect) and are not in violation of any term of any such Authorizations, except where the failure to possess such Authorization or the violation of such Authorization would not, individually or in the aggregate, result in a Material Adverse Effect; (vi) have not received written notice of any pending or threatened claim, suit, proceeding, clinical hold, hearing, enforcement, audit, investigation, arbitration, suspension, debarment or exclusion from any governmental authority or Institutional Review Board alleging that any of their respective operations or activities is in violation of any Applicable Laws or Authorizations and the Company has no knowledge or reason to believe that any such governmental authority, Institutional Review Board or other non-governmental authority is considering any such claim, suit, proceeding, clinical hold, hearing, enforcement, audit, investigation, arbitration, suspension, debarment or exclusion except for any such claims, suits, proceedings, clinical holds, hearings, enforcements, audits, investigations, arbitrations, suspensions, debarments or exclusions that would not, individually or in the aggregate, result in a Material Adverse Effect; (vii) have not received written notice that any governmental authority or Institutional Review Board has taken, is taking or intends to take action to limit, suspend, modify or revoke any Authorizations and the Company has no knowledge or reason to believe that any such governmental authority is considering such action, except for any such actions that would not, individually or in the aggregate, result in a Material Adverse Effect; (viii) have, or have had on their behalf, filed, declared, obtained, maintained or submitted all reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as are required by any Applicable Laws or Authorizations, except where the failure to so file, declare, obtain, maintain or submit would not, individually or in the aggregate, result in a Material Adverse Effect and all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were materially complete and correct on the date filed (or were corrected or supplemented by a subsequent submission); and (ix) have not, either voluntarily or involuntarily, initiated, conducted or issued, or caused to be initiated, conducted or issued, any recall, market withdrawal or replacement, safety alert, warning, “dear doctor” letter or investigator notice relating to an alleged lack of safety or efficacy of any product or product candidate, any alleged product defect, or violation of any material Applicable Laws or Authorizations and the Company is not aware of any facts that would cause the Company or any of its subsidiaries to initiate any such notice or action and the Company has no knowledge or reason to believe that any governmental authority, Institutional Review Board or other non-governmental authority intends to initiate any such notice or action, except for any such notices or actions that would not, individually or in the aggregate, result in a Material Adverse Effect. Any clinical trials conducted by or on behalf of the Company or any of its subsidiaries that are described in the Registration Statement, the General Disclosure Package or the Prospectus were and, if still pending, are being conducted in compliance in all material respects with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all applicable federal, state, local and foreign laws, rules and regulations, including, but not limited to, the Federal Food, Drug, and Cosmetic Act and implementing regulations at 21 C.F.R. Parts 50, 54, 56, 58 and 312. Any descriptions of studies, tests and preclinical and clinical trials, including any related results and regulatory status, contained in the Registration Statement, the General Disclosure Package or the Prospectus are, and will be, accurate and complete in all material respects. The Company is not aware of any studies, tests or trials the results of which reasonably call into question in any material respect the clinical trial results described or referred to in the Registration Statement, the General Disclosure Package or the Prospectus. Neither the Company nor any of its subsidiaries has received any written notices or other correspondence from the FDA, an Institutional Review Board or other governmental agency requiring or recommending the termination, suspension or material modification of any clinical trials conducted by, or on behalf of, the Company or any of its subsidiaries or in which the Company or any of its subsidiaries has participated.